Lifebit and Flatiron Health have announced a multi-year strategic partnership with the aim of improving scientific discoveries by learning from the experience of cancer patients.
Health data generated by hospitals, healthcare providers, research organisations and clinical trials hold the potential to advance research and innovation, improve patient care and accelerate drug development.
The sensitivity of these data requires the utmost security and privacy measures that demonstrate strict compliance with global data use regulations to ensure patient data protection, and build patient confidence and trust in the use of their data for research.
Lifebit’s Trusted Research Environment technology provides real-world data on cancer patients. The strict access controls set on the platform ensures the data are not shared or accessed without approval nor used for any purpose other than approved research.
Flatiron Health works across the United Kingdom, Germany, US and Japan in collaboration with hospitals and health networks to design real-world data approaches tailored to each country.
“This partnership will continue to help improve treatment, care and quality of life of people with cancer,” said Dr Arun Sujenthiran, UK Clinical Lead and Senior Medical Director, Flatiron Health.
“At Lifebit we are proud to announce this important partnership with Flatiron and we are excited about the possible outcomes for cancer research,” commented Dr Chiara Bacchelli, Precision Medicine and Human Genetics Lead at Lifebit.
